A carregar...
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B...
Na minha lista:
| Publicado no: | Leukemia |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7862069/ https://ncbi.nlm.nih.gov/pubmed/33122850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-01072-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|